Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING NYMALIZE (nimodipine) Oral Solution 6 mg/mL is a pale yellow solution and is supplied as follows: NDC 24338-260-08: 8 oz. bottle (237 mL) 60 mg/10 mL (6 mg/mL) NDC 24338-260-12: Carton containing 12 individually wrapped 10 mL packages. Each package contains one 60 mg/10 mL unit-dose prefilled oral syringe with a purple plunger (NDC 24338-260-10). NDC 24338-230-12: Carton containing 12 individually wrapped 5 mL packages. Each package contains one 30 mg/5 mL unit-dose prefilled oral syringe with a white plunger (NDC 24338-230-05). NDC 24338-230-30: Carton containing 12 blisters. Each blister contains one 30 mg/5 mL unit-dose prefilled ENFit ® oral syringe (NDC 24338-230-15). Store between 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from light. Do not refrigerate.; PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label Mfg. for Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg. by Safecor Health Columbus, OH NDC 2433826010 Store at controlled room temperature, USP. Protect from light. Do not refrigerate. Nymalize ® (nimodipine) oral solution 60 mg/10 mL For Oral Use Only Rx Only Rev. 05/22 Lot XXXXXXX Exp. YYYY-MM-DD PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label; PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package 10 mL Nymalize ® (nimodipine) oral solution 60 mg / 10 mL For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children Package not child resistant Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F - 86°F) [see USP Controlled Room Temperature] Protect from light Do not refrigerate NDC: 24338-260-10 One 10 mL Unit-Dose Oral Syringe Rx Only EXP: 2023-05-31 Lot: 22A0047 Mfg For Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg By Safecor, Columbus, OH 43204 NYM-OW10-S01 REV. 05/22 PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package; PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package Carton NDC: 24338-260-12 Rx Only Nymalize ® (nimodipine) oral solution 60 mg/10 mL Contains 12 Prefilled Oral Syringes For Oral Use Only Distributed by: azurity ® pharmaceuticals Woburn, MA 01801 PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package Carton; PRINCIPAL DISPLAY PANEL - 5 mL Syringe Label Mfg. for Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg. by Safecor Health Columbus, OH NDC 2433823005 Store at controlled room temperature, USP. Protect from light. Do not refrigerate. Nymalize ® (nimodipine) oral solution 30 mg/5 mL For Oral Use Only Rx Only Rev. 05/22 Lot XXXXXXX Exp. YYYY-MM-DD PRINCIPAL DISPLAY PANEL - 5 mL Syringe Label; PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package 5 mL Nymalize ® (nimodipine) oral solution 30 mg / 5 mL For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children Package not child resistant Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F - 86°F) [see USP Controlled Room Temperature] Protect from light Do not refrigerate NDC: 24338-230-05 One 5 mL Unit-Dose Oral Syringe Rx Only EXP: 2023-04-30 Lot: 22A0060 Mfg For Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg By Safecor, Columbus, OH 43204 NYM-OW05-S01 REV. 05/22 PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package; PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package Carton NDC: 24338-230-12 Rx Only Nymalize ® (nimodipine) oral solution 30 mg/5 mL Contains 12 Prefilled Oral Syringes For Oral Use Only Distributed by: azurity ® pharmaceuticals Woburn, MA 01801 PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package Carton; PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Label NDC 24338-230-15 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit ® Syringe For Oral Use Only 5 mL ENFit® Syringe Label; PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Blister Label NDC 24338-230-15 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit ® Syringe One 5 mL ENFit ® Syringe For Oral Use Only Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F- 86°F). [see USP Controlled Room Temperature] Protect from light. Do not refrigerate. Manufactured for: azurity ® Pharmaceuticals Woburn, MA 01801 5 mL ENFit® Syringe Blister Label; PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Carton Label NDC 24338-230-30 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit® Syringe Contains 12 Prefilled ENFit ® Oral Syringes For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children. Package not child resistant. Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F- 86°F). [see USP Controlled Room Temperature] Protect from light. Do not refrigerate. Manufactured for: azurity® Pharmaceuticals Woburn, MA 01801 5 mL ENFit® Syringe Carton Label
- 16 HOW SUPPLIED/STORAGE AND HANDLING NYMALIZE (nimodipine) Oral Solution 6 mg/mL is a pale yellow solution and is supplied as follows: NDC 24338-260-08: 8 oz. bottle (237 mL) 60 mg/10 mL (6 mg/mL) NDC 24338-260-12: Carton containing 12 individually wrapped 10 mL packages. Each package contains one 60 mg/10 mL unit-dose prefilled oral syringe with a purple plunger (NDC 24338-260-10). NDC 24338-230-12: Carton containing 12 individually wrapped 5 mL packages. Each package contains one 30 mg/5 mL unit-dose prefilled oral syringe with a white plunger (NDC 24338-230-05). NDC 24338-230-30: Carton containing 12 blisters. Each blister contains one 30 mg/5 mL unit-dose prefilled ENFit ® oral syringe (NDC 24338-230-15). Store between 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from light. Do not refrigerate.
- PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label Mfg. for Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg. by Safecor Health Columbus, OH NDC 2433826010 Store at controlled room temperature, USP. Protect from light. Do not refrigerate. Nymalize ® (nimodipine) oral solution 60 mg/10 mL For Oral Use Only Rx Only Rev. 05/22 Lot XXXXXXX Exp. YYYY-MM-DD PRINCIPAL DISPLAY PANEL - 10 mL Syringe Label
- PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package 10 mL Nymalize ® (nimodipine) oral solution 60 mg / 10 mL For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children Package not child resistant Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F - 86°F) [see USP Controlled Room Temperature] Protect from light Do not refrigerate NDC: 24338-260-10 One 10 mL Unit-Dose Oral Syringe Rx Only EXP: 2023-05-31 Lot: 22A0047 Mfg For Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg By Safecor, Columbus, OH 43204 NYM-OW10-S01 REV. 05/22 PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package
- PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package Carton NDC: 24338-260-12 Rx Only Nymalize ® (nimodipine) oral solution 60 mg/10 mL Contains 12 Prefilled Oral Syringes For Oral Use Only Distributed by: azurity ® pharmaceuticals Woburn, MA 01801 PRINCIPAL DISPLAY PANEL - 10 mL Syringe Package Carton
- PRINCIPAL DISPLAY PANEL - 5 mL Syringe Label Mfg. for Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg. by Safecor Health Columbus, OH NDC 2433823005 Store at controlled room temperature, USP. Protect from light. Do not refrigerate. Nymalize ® (nimodipine) oral solution 30 mg/5 mL For Oral Use Only Rx Only Rev. 05/22 Lot XXXXXXX Exp. YYYY-MM-DD PRINCIPAL DISPLAY PANEL - 5 mL Syringe Label
- PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package 5 mL Nymalize ® (nimodipine) oral solution 30 mg / 5 mL For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children Package not child resistant Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F - 86°F) [see USP Controlled Room Temperature] Protect from light Do not refrigerate NDC: 24338-230-05 One 5 mL Unit-Dose Oral Syringe Rx Only EXP: 2023-04-30 Lot: 22A0060 Mfg For Azurity Pharmaceuticals, Inc. Woburn, MA 01801 Pkg By Safecor, Columbus, OH 43204 NYM-OW05-S01 REV. 05/22 PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package
- PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package Carton NDC: 24338-230-12 Rx Only Nymalize ® (nimodipine) oral solution 30 mg/5 mL Contains 12 Prefilled Oral Syringes For Oral Use Only Distributed by: azurity ® pharmaceuticals Woburn, MA 01801 PRINCIPAL DISPLAY PANEL - 5 mL Syringe Package Carton
- PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Label NDC 24338-230-15 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit ® Syringe For Oral Use Only 5 mL ENFit® Syringe Label
- PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Blister Label NDC 24338-230-15 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit ® Syringe One 5 mL ENFit ® Syringe For Oral Use Only Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F- 86°F). [see USP Controlled Room Temperature] Protect from light. Do not refrigerate. Manufactured for: azurity ® Pharmaceuticals Woburn, MA 01801 5 mL ENFit® Syringe Blister Label
- PRINCIPAL DISPLAY PANEL - 5 mL ENFit® Syringe Carton Label NDC 24338-230-30 Rx Only Nymalize® (nimodipine) oral solution 30 mg/5 mL ENFit® Syringe Contains 12 Prefilled ENFit ® Oral Syringes For Oral Use Only Recommended Dosage: See prescribing information. Keep out of reach of children. Package not child resistant. Store between 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F- 86°F). [see USP Controlled Room Temperature] Protect from light. Do not refrigerate. Manufactured for: azurity® Pharmaceuticals Woburn, MA 01801 5 mL ENFit® Syringe Carton Label
Overview
NYMALIZE contains nimodipine, a dihydropyridine calcium channel blocker. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-( m -nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C 21 H 26 N 2 O 7 . The structural formula is: Nimodipine is a yellow crystalline substance, practically insoluble in water. NYMALIZE Oral Solution contains 60 mg of nimodipine per 10 mL. In addition, the oral solution contains the following inactive ingredients: ethanol, glycerin, methylparaben, polyethylene glycol 400. Chemical Structure
Indications & Usage
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). NYMALIZE is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). ( 1 )
Dosage & Administration
Administer only enterally (e.g., oral, nasogastric tube, or gastric tube route). Do not administer intravenously or by other parenteral routes. ( 2.1 ) Give one hour before a meal or two hours after a meal. ( 2.1 ) Start dosing within 96 hours of the SAH. ( 2.1 ) Recommended dose is 10 mL (60 mg) every 4 hours for 21 consecutive days. ( 2.2 ) Nasogastric or Gastric Tube Administration: Administer 10 mL (60 mg) every 4 hours with supplied prefilled oral syringe. Refill syringe with 10 mL of 0.9% saline water solution; flush remaining contents from nasogastric or gastric tube into stomach. ( 2.3 ) Patients with Cirrhosis: Reduce dosage to 5 mL (30 mg) every 4 hours. ( 2.4 ) 2.1 Administration Instructions Administer only enterally (e.g., oral, nasogastric tube, or gastric tube route). Do not administer intravenously or by other parenteral routes. For all routes of administration, begin NYMALIZE within 96 hours of the onset of SAH. Administer one hour before a meal or two hours after a meal for all routes of administration [see Clinical Pharmacology (12.3) ] . 2.2 Administration by Oral Route The recommended oral dosage is 10 mL (60 mg) every 4 hours for 21 consecutive days. 2.3 Administration Via Nasogastric or Gastric Tube Using the supplied prefilled oral syringe labeled "For Oral Use Only", administer 10 mL (60 mg) every 4 hours into a nasogastric or gastric tube for 21 consecutive days. For each dose, refill the syringe with 10 mL of 0.9% saline solution and then flush any remaining contents from nasogastric or gastric tube into the stomach. 2.4 Dosage Adjustments in Patients with Cirrhosis In patients with cirrhosis, reduce the dosage to 5 mL (30 mg) every 4 hours [ s ee Warnings and Precautions (5.2) , Clinical Pharmacology (12.3) ] .
Warnings & Precautions
Hypotension: Monitor blood pressure. ( 5.1 ) Patients with Cirrhosis: Higher risk of adverse reactions. Monitor blood pressure and pulse. ( 5.2 ) CYP3A4 Strong Inhibitors: May significantly increase risk of hypotension. Concomitant use with NYMALIZE should generally be avoided. ( 5.3 ) CYP3A4 Strong Inducers: May significantly reduce efficacy of nimodipine. Concomitant use with NYMALIZE should generally be avoided. ( 5.4 ) 5.1 Hypotension Blood pressure should be carefully monitored during treatment with NYMALIZE. In clinical studies of patients with subarachnoid hemorrhage, about 5% of nimodipine-treated patients compared to 1% of placebo-treated patients had hypotension and about 1% of nimodipine-treated patients left the study because of this [see Adverse Reactions (6) ]. 5.2 Possible Increased Risk of Adverse Reactions in Patients with Cirrhosis Given that the plasma levels of nimodipine are increased in patients with cirrhosis, these patients are at higher risk of adverse reactions. Therefore, monitor blood pressure and pulse rate closely and administer a lower dosage [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . 5.3 Possible Increased Risk of Hypotension with Strong CYP3A4 Inhibitors Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (e.g., boceprevir, telaprevir), some azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone with nimodipine should generally be avoided because of a risk of significant hypotension [see Drug Interactions (7.2) ] . 5.4 Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort) and nimodipine should generally be avoided, as nimodipine plasma concentration and efficacy may be significantly reduced [see Drug Interactions (7.3) ].
Contraindications
None. None ( 4 )
Adverse Reactions
The safety and efficacy of NYMALIZE (nimodipine oral solution) in the treatment of patients with SAH is based on adequate and well-controlled studies of nimodipine oral capsules in patients with SAH. NYMALIZE (nimodipine oral solution) has comparable bioavailability to nimodipine oral capsules. The following clinically significant adverse reaction appears in other sections of the labeling: Hypotension [see Warnings and Precautions (5.1) ]. Most common adverse reactions (incidence ≥1% and ≥1% placebo) were hypotension, headache, nausea, and bradycardia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In clinical trials of nimodipine oral capsules in patients with SAH, eleven percent (92 of 823) of nimodipine-treated patients reported adverse events compared to six percent (29 of 479) of placebo-treated patients. The most common adverse event was decreased blood pressure in 4.4% of nimodipine-treated patients. The events reported with a frequency greater than 1% are displayed in Table 1 by dose. Table 1: Adverse Events [n (%)] reported with a frequency > 1% in four clinical trials (Study 1, Study 2, Study 3, and Study 4) Placebo (n=479) Nimodipine dose every 4 hours 0.35 mg/kg (n=82) 30 mg (n=71) 60 mg (n=494) 90 mg (n=172) 120 mg (n=4) Decreased Blood Pressure 6 (1.2) 1 (1.2) 0 19 (3.8) 14 (8.1) 2 (50.0) Edema 3 (0.6) 0 0 2 (0.4) 2 (1.2) 0 Diarrhea 3 (0.6) 0 3 (4.2) 0 3 (1.7) 0 Rash 3 (0.6) 2 (2.4) 0 3 (0.6) 2 (1.2) 0 Headache 1 (0.2) 0 1 (1.4) 6 (1.2) 0 0 Gastrointestinal Symptoms 0 2 (2.4) 0 0 2 (1.2) 0 Nausea 0 1 (1.2) 1 (1.4) 6 (1.2) 1 (0.6) 0 Dyspnea 0 1 (1.2) 0 0 0 0 EKG Abnormalities 0 0 1 (1.4) 0 1 (0.6) 0 Tachycardia 0 0 1 (1.4) 0 0 0 Bradycardia 0 0 0 5 (1.0) 1 (0.6) 0 Muscle Pain/Cramp 0 0 1 (1.4) 1 (0.2) 1 (0.6) 0 Acne 0 0 1 (1.4) 0 0 0 Depression 0 0 1 (1.4) 0 0 0 SAH is frequently accompanied by alterations in consciousness that may lead to an under-reporting of adverse experiences. As a calcium channel blocker, nimodipine may have the potential to exacerbate heart failure in susceptible patients or to interfere with A-V conduction, but these events were not observed in SAH trials.
Drug Interactions
Anti-Hypertensives : May increase risk of hypotension. Monitor blood pressure. ( 7.1 ) CYP3A4 Moderate and Weak Inhibitors: May increase risk of hypotension. Monitor blood pressure. Dose reduction of NYMALIZE may be needed. Avoid grapefruit juice. ( 7.2 ) CYP3A4 Moderate and Weak Inducers: May reduce efficacy of NYMALIZE. Dose increase may be needed. ( 7.3 ) 7.1 Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. In Europe, nimodipine was observed to occasionally intensify the effect of antihypertensive drugs taken concomitantly by hypertensive patients; this phenomenon was not observed in North American clinical trials. Blood pressure should be carefully monitored, and dose adjustment of the blood pressure lowering drug(s) may be necessary. 7.2 CYP3A4 Inhibitors Nimodipine plasma concentration can be significantly increased when concomitantly administered with strong CYP3A4 inhibitors. As a consequence, the blood pressure lowering effect may be increased. Therefore, the concomitant administration of NYMALIZE and strong CYP3A4 inhibitors should generally be avoided [ see Warnings and Precautions (5.3) ]. Strong CYP3A4 inhibitors include some members of the following classes: macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), HCV protease inhibitors (e.g., boceprevir, telaprevir), azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, nefazodone Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4. If nimodipine is concomitantly administered with these drugs, blood pressure should be monitored, and a reduction of the nimodipine dose may be necessary. Moderate and weak CYP3A4 inhibitors include alprozalam, ameprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinuprestin/dalfopristin, valproic acid, and verapamil. A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one-week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day. This effect may be mediated by the known inhibition of hepatic cytochrome P-450 (CYP) by cimetidine, which could decrease first-pass metabolism of nimodipine. Grapefruit juice inhibits CYP3A4. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine. 7.3 CYP3A4 Inducers Nimodipine plasma concentration and efficacy may be significantly reduced when concomitantly administered with strong CYP3A4 inducers. Therefore, concomitant use of NYMALIZE with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort) should generally be avoided [see Warnings and Precautions (5.4) ] . Moderate and weak inducers of CYP3A4 may also reduce the efficacy of nimodipine. Patients on these should be closely monitored for lack of effectiveness, and a nimodipine dosage increase may be required. Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib.
Storage & Handling
Store between 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from light. Do not refrigerate.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.